443 related articles for article (PubMed ID: 30085324)
1. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM
Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324
[TBL] [Abstract][Full Text] [Related]
2. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
3. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
[TBL] [Abstract][Full Text] [Related]
4. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
7. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
[TBL] [Abstract][Full Text] [Related]
8. Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
Giamarellos-Bourboulis EJ; Sobell J; Ryan C; Wolkenstein PJ; Geng Z; Mulder GD
Wounds; 2017 Nov; 29(11):E98-E102. PubMed ID: 29166256
[TBL] [Abstract][Full Text] [Related]
9. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
Clin Exp Dermatol; 2021 Mar; 46(2):306-313. PubMed ID: 32931599
[TBL] [Abstract][Full Text] [Related]
10. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
[TBL] [Abstract][Full Text] [Related]
11. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES; Garnock-Jones KP; Keam SJ
Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
[TBL] [Abstract][Full Text] [Related]
15. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
Tzellos T; van Straalen KR; Kyrgidis A; Alavi A; Goldfarb N; Gulliver W; Jemec GBE; Lowes MA; Marzano AV; Prens EP; Sayed CJ; van der Zee HH; Zouboulis CC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
19. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.
Morita A; Takahashi H; Ozawa K; Imafuku S; Takekuni N; Takahashi K; Matsuyama T; Okubo Y; Zhao Y; Kitamura S; Takei K; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2021 Jan; 48(1):3-13. PubMed ID: 33029861
[TBL] [Abstract][Full Text] [Related]
20. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
Scheinfeld N; Sundaram M; Teixeira H; Gu Y; Okun M
Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
